ESMO Open Podcast-logo

ESMO Open Podcast

Health & Wellness Podcasts >

More Information


United States






Recent advances in adjuvant therapy for melanoma patients

In the last decade, we have seen a significant change in the therapeutic landscape for advanced melanoma. Recently, results from two trials evaluating immunotherapy and targeted therapy in the adjuvant setting (completely resected stage III/IV) were published. In this podcast, Teresa Amaral, member of the ESMO YOC, talks with Professor Jeffrey Weber, Professor of Oncology and Deputy Director of the Laura and Isaac Perlmutter Cancer Center, about the recent developments in adjuvant...


New therapeutic targets in the inflammatory microenvironment

In this podcast, Editor Anna Berghoff speaks to Professor Eric Tartour (Department of Immunology; Hôpital Européen Georges Pompidou) about new therapeutic targets in the inflammatory microenvironment. The introduction of immune checkpoint inhibitors introduced a new era of oncology. The CTLA4 or PD1/PDL1 axis targeting immune checkpoint inhibitors have shown remarkable and long lasting responses in a variety of tumor types, Here, the biology of immune checkpoint inhibitors is outlined...


Heterogeneity of colon cancer: from bench to bedside

Professor Marco Merlano, Oncology Department Santa Croce e Carle, General Hospital, Italy, is the leading author of the ESMO Open article ‘Heterogeneity of colon cancer: from bench to bedside’, summarised in this podcast. Abstract The large bowel shows biomolecular, anatomical and bacterial changes that proceed from the proximal to the distal tract. These changes account for the different behaviour of colon cancers arising from the diverse sides of the colon–rectum as well as for the...


ASCO - Practice changing studies in gastrointestinal cancer

In this podcast new, practice-changing research in gastrointestinal (GI) cancer is considered. Clinical trials focusing on immunotherapies presented at the recent ASCO Gastrointestinal Cancers Symposium in San Francisco are discussed. Highlights include reports of the ONO-4538 study, in which pretreated gastric cancer patients were randomized to receive either nivolumab or best supportive care, and of the CheckMate 040 study in which pretreated patients with hepatocellular carcinoma...


New horizon in breast cancer therapy - ESMO congress, ASCO and San Antonio Symposium’s highlights

Elżbieta Senkus, Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdańsk, Poland, ( presents an overview of new therapies on the horizon for breast cancer in terms of data presented at the ESMO Congress, ASCO, and the San Antonio Breast Cancer Symposium. In the adjuvant setting, results from the MINDACT trial, which evaluated genomic versus clinical assessment for risk stratification, are described. Data on the role of anthracyclines in adjuvant...


ASCO Highlights podcast: Head and neck cancers

These highlights are presented by Marco Merlano, Department of Medical Oncology, Santa Croce General Hospital, Cuneo, Italy,( A critical review of the head and neck cancer research highlights of the American Society of Clinical Oncology (ASCO) meeting 2016, held in June 2016 in Chicago, is presented in this podcast. Considering the most interesting and practice-changing trials reported at the meeting, the key trial comparing gemcitabine plus cisplatin against 5-FU plus...


The Cancer Genome - Highlights of a Nature Medicine Perspective

These highlights are presented by Emile Voest, The Netherlands Cancer Institute - Molecular Oncology, Amsterdam, Netherlands ( The author reviews the recently published article “Facilitating a Culture of Responsible and Effective Sharing of Cancer Genome Data” (Nat Med. 2016 May 5;22(5):464-71 - considering why data sharing is important and explaining the obstacles and problems involved. The need to identify common bioinformatics pipelines and resolve...


Highlights from the ESMO Symposium on Signalling Pathways in Cancer 2016

A critical review of the highlights of the ESMO Symposium on Signalling Pathways in Cancer 2016, held March 2016 in partnership with the European Association of Cancer Research, is presented in this podcast. The meeting addressed developments in personalized medicine associated with the HER/EGFR family. Key subjects discussed were the bases of the mechanisms of signal transduction and primary and secondary resistance to EGFR-inhibiting drugs, and the emergence of better characterized...


Try Premium for 30 days

Live games for all NFL, MLB, NBA, & NHL teams
Commercial-Free Music
No Display Ads